APHA has been the subject of a number of other research reports. Cormark set a $15.00 price objective on Aphria and gave the company a buy rating in a research note on Saturday, February 2nd. CIBC initiated coverage on Aphria in a report on Friday, January 18th. They issued a neutral rating for the company. Canaccord Genuity restated a buy rating on shares of Aphria in a report on Wednesday, December 5th. Seaport Global Securities assumed coverage on Aphria in a research report on Thursday, February 21st. They set a buy rating and a $18.00 price objective on the stock. Finally, Eight Capital cut Aphria to a hold rating and set a $7.00 target price on the stock. in a research report on Thursday, December 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. Aphria currently has a consensus rating of Hold and an average target price of $15.69.
APHA traded up $0.09 during midday trading on Monday, hitting $7.90. The stock had a trading volume of 80,556 shares, compared to its average volume of 6,802,128. The firm has a market cap of $1.96 billion, a P/E ratio of 55.86 and a beta of 4.08. Aphria has a 1 year low of $3.75 and a 1 year high of $16.86.
Aphria Company Profile
Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.
Featured Article: What are Closed-End Mutual Funds?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.